Cytokine induction by purified lipoteichoic acids from various bacterial species - Role of LBP, sCD14, CD14 and failure to induce IL-12 and subsequent IFN-γ release
- 1 February 2002
- journal article
- research article
- Published by Wiley in European Journal of Immunology
- Vol. 32 (2) , 541-551
- https://doi.org/10.1002/1521-4141(200202)32:2<541::aid-immu541>3.0.co;2-p
Abstract
We have recently shown that highly purified lipoteichoic acid (LTA) represents a major immunostimulatory principle of Staphylococcus aureus. In order to test whether this translates to other bacterial species, we extracted and purified LTA from 12 laboratory-grown species. All LTA induced the release of TNF-α, IL-1β, IL-6 and IL-10 in human whole blood. Soluble CD14 (sCD14) inhibited monokine induction by LTA but failed to confer LTA responsiveness for IL-6 and IL-8 release of human umbilical vein endothelial cells (HUVEC). In a competitive LPS-binding protein (LBP) binding assay, the IC50 of the tested LTA preparations was up to 3,230-fold higher than for LPS. LBP enhanced TNF-α release of human peripheral blood mononuclear cells (PBMC) upon LPSbut not LTA stimulation. These data demonstrate a differential role for the serum proteins LBP and sCD14 in the recognition of LPS and LTA. Different efficacies of various anti-CD14 antibodies against LPS vs. LTA-induced cytokine release suggest that the recognition sites of CD14 for LPS and LTA are distinct with a partial overlap. While the maximal achievable monokine release in response toLTA was comparable to LPS, all LTA induced significantly less IL-12 and IFN-γ. IL-12 substitution increased LTA-inducible IFN-γ release up to 180-fold, suggesting a critical role of poor LTA-inducible IL-12 for IFN-γ formation. Pretreatment with IFN-γ rendered galactosamine-sensitized mice sensitive to challenge with LTA. In conclusion, LTA compared to LPS, are weak inducers of IL-12 and subsequent IFN-γ formation which might explain their lower toxicity in vivo.Keywords
This publication has 40 references indexed in Scilit:
- Structure–Function Relationship of Cytokine Induction by Lipoteichoic Acid fromStaphylococcus aureusThe Journal of Experimental Medicine, 2001
- Commercial Preparations of Lipoteichoic Acid Contain Endotoxin That Contributes to Activation of Mouse Macrophages In VitroInfection and Immunity, 2001
- Bacterial Lipopolysaccharide Activates NF-κB through Toll-like Receptor 4 (TLR-4) in Cultured Human Dermal Endothelial CellsJournal of Biological Chemistry, 2000
- LPS-binding protein protects mice from septic shock caused by LPS or gram-negative bacteria.Journal of Clinical Investigation, 1998
- Mutation of Amino Acids 39–44 of Human CD14 Abrogates Binding of Lipopolysaccharide and Escherichia coliEuropean Journal of Biochemistry, 1997
- Macrophage Inflammatory Protein-1α Expression in Vivo and in Vitro: The Role of Lipoteichoic AcidClinical Immunology and Immunopathology, 1995
- CD14 Is a pattern recognition receptorImmunity, 1994
- Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14.The Journal of Experimental Medicine, 1994
- Endotoxin-neutralizing capacity of soluble CD14Research in Immunology, 1992
- Improved Preparation of Lipoteichoic AcidsEuropean Journal of Biochemistry, 1983